Raleukin

Raleukin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Dec 24;10(1):417. [Abstract]

Customer Validation
Bioluminescence imaging (BLI) on days 0, 5, and 10 posttreatment in BM-bearing mice. The treatment groups included vehicle, Raleukin (Anakinra) (100 mg/kg, intraperitoneally, daily), SH4-54 (10 mg/kg every 3 days), and anakinra + SH4-54.

Raleukin purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Jul 16. [Abstract]

Customer Validation
Representative images and quantification of liver lesions in BALB/c mice intrasplenically injected with CT26 following AAV-SPHK1 or Anakinra (Raleukin) (500 µg; intraperitoneal injection on days 4, 7, 10, 13, and 16) treatment.

Raleukin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2025 Apr 7. [Abstract]

Customer Validation
Ifnγ relative expression (n=3) in Th17 cells differentiated from CD4 Nlrp3-/- mice and their littermate (Lit) controls treated with CASPASE-1 inhibitor (ZYVAD), CASPASE-8 inhibitor (ZIETD), inflammasome inhibitor (MCC950), or Anakinra (Anak) (Raleukin) (300 nM).

Raleukin purchased from MedChemExpress. Usage Cited in: Nat Nanotechnol. 2024 Mar;19(3):387-398. [Abstract]

Customer Validation
Effect of IL-1 receptor blockage (IL-1RA, Raleukin) (50 mg/kg, daily) on the lineage shifts of haematopoietic progenitor cells due to administration of OMVs: schematic illustration of the experimental schedule and grouping information (c); frequency of LSKs in Lin-cells, ST-HSCs and MPPs in LSKs as determined by flow cytometry.

Raleukin purchased from MedChemExpress. Usage Cited in: Circulation. 2021 Sep 14;144(11):893-908. [Abstract]

Customer Validation
Adhesion of DiI-labeled peripheral blood mononuclear cells (PBMCs) stimulated with TNF-α (18 hours), LPS (18 hours), LPS plus OA (18 hours for LPS priming, 4 hours), or LPS plus oxalate (18 hours for LPS priming, 4 hours) to human aortic endothelial cells (HAECs) as determined by fluorescence microscopy (n=3 per group) in the presence of an anti-IL-1α blocking antibody (1 µg/mL) incubated with PBMCs or an anti-IL-1R1 blocking antibody (Raleukin, 500 ng/mL) incubated with HAECs (10 µg/mL) or an isotype control.